Daiichi Sankyo begins patient dosing in QuANTUM-Wild phase 3 trial of Vanflyta in newly diagnosed FLT3-ITD negative AML
The first patient has been dosed in the QuANTUM-Wild phase 3 trial evaluating Daiichi Sankyo’s Vanflyta (quizartinib) in combination with standard intensive induction and consolidation chemotherapy followed by single-agent maintenance in adults with newly …